Follow
Michael Shultz
Title
Cited by
Cited by
Year
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
SMA Huang, YM Mishina, S Liu, A Cheung, F Stegmeier, GA Michaud, ...
Nature 461 (7264), 614-620, 2009
21722009
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
YNP Chen, MJ LaMarche, HM Chan, P Fekkes, J Garcia-Fortanet, ...
Nature 535 (7610), 148-152, 2016
7722016
Two decades under the influence of the rule of five and the changing properties of approved oral drugs: miniperspective
MD Shultz
Journal of Medicinal Chemistry 62 (4), 1701-1714, 2018
3502018
Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor
J Garcia Fortanet, CHT Chen, YNP Chen, Z Chen, Z Deng, B Firestone, ...
Journal of medicinal chemistry 59 (17), 7773-7782, 2016
2592016
Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters
MD Shultz
Bioorganic & medicinal chemistry letters 23 (21), 5980-5991, 2013
2032013
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors
L Whitehead, MR Dobler, B Radetich, Y Zhu, PW Atadja, T Claiborne, ...
Bioorganic & medicinal chemistry 19 (15), 4626-4634, 2011
1772011
Targeting the dimerization interface of HIV-1 protease: inhibition with cross-linked interfacial peptides
R Zutshi, J Franciskovich, M Shultz, B Schweitzer, P Bishop, M Wilson, ...
Journal of the American Chemical Society 119 (21), 4841-4845, 1997
1611997
Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer
MJ LaMarche, M Acker, A Argintaru, D Bauer, J Boisclair, H Chan, ...
Journal of medicinal chemistry 63 (22), 13578-13594, 2020
1292020
Identification of NVP-TNKS656: the use of structure–efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor
MD Shultz, AK Cheung, CA Kirby, B Firestone, J Fan, CHT Chen, Z Chen, ...
Journal of medicinal chemistry 56 (16), 6495-6511, 2013
1272013
Dual allosteric inhibition of SHP2 phosphatase
M Fodor, E Price, P Wang, H Lu, A Argintaru, Z Chen, M Glick, HX Hao, ...
ACS chemical biology 13 (3), 647-656, 2018
1122018
Discovery of first-in-class, potent, and orally bioavailable embryonic ectoderm development (EED) inhibitor with robust anticancer efficacy
Y Huang, J Zhang, Z Yu, H Zhang, Y Wang, A Lingel, W Qi, J Gu, K Zhao, ...
Journal of medicinal chemistry 60 (6), 2215-2226, 2017
1022017
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations
MD Shultz
Bioorganic & medicinal chemistry letters 23 (21), 5992-6000, 2013
992013
Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor
YS Cho, JR Levell, G Liu, T Caferro, J Sutton, CM Shafer, A Costales, ...
ACS medicinal chemistry letters 8 (10), 1116-1121, 2017
962017
[1, 2, 4] triazol-3-ylsulfanylmethyl)-3-phenyl-[1, 2, 4] oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding
MD Shultz, CA Kirby, T Stams, DN Chin, J Blank, O Charlat, H Cheng, ...
Journal of Medicinal Chemistry 55 (3), 1127-1136, 2012
822012
Improving the plausibility of success with inefficient metrics
MD Shultz
ACS medicinal chemistry letters 5 (1), 2-5, 2014
742014
Size dependent magnetic properties and cation inversion in chemically synthesized MnFe2O4 nanoparticles
CN Chinnasamy, A Yang, SD Yoon, K Hsu, MD Shultz, EE Carpenter, ...
Journal of applied physics 101 (9), 2007
732007
Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939
CA Kirby, A Cheung, A Fazal, MD Shultz, T Stams
Acta Crystallographica Section F: Structural Biology and Crystallization …, 2012
662012
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors
MD Shultz, X Cao, CH Chen, YS Cho, NR Davis, J Eckman, J Fan, ...
Journal of medicinal chemistry 54 (13), 4752-4772, 2011
662011
Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach
MD Shultz, YW Ham, SG Lee, DA Davis, C Brown, J Chmielewski
Journal of the American Chemical Society 126 (32), 9886-9887, 2004
592004
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
TR Caferro, YS Cho, AQ Costales, H Lei, F Lenoir, JR Levell, G Liu, ...
US Patent 8,957,068, 2015
562015
The system can't perform the operation now. Try again later.
Articles 1–20